PDUFA III “Good Review Management Principles” To Stress Early Action
Executive Summary
FDA's "Good Review Management Principles" guidance will recognize the need for the completion of second- and third-round reviews of NDAs and BLAs before the action goal date under the Prescription Drug User Fee Act III
You may also be interested in...
FDA “Independent Consultant” Guidance Implements PDUFA III Provision
FDA is ruling out the use of prospective clinical trial investigators as independent consultants for protocol reviews requested by sponsors, the agency indicated in a draft guidance
FDA “Independent Consultant” Guidance Implements PDUFA III Provision
FDA is ruling out the use of prospective clinical trial investigators as independent consultants for protocol reviews requested by sponsors, the agency indicated in a draft guidance
FDA Has “Issues” With NDAs; Half Of 74-Day Letters Note Application Flaws
About half of the 74-day "issue" letters sent by FDA to NDA applicants in the first six months of the agency's 2003 fiscal year have noted application flaws, Office of New Drugs Director John Jenkins, MD, said at Temple University's annual industry/FDA conference in Philadelphia April 15